Skip to main content

Celcuity stock soars after hours on breakthrough therapy designation for cancer drug

Shares of Celcuity Inc. were up 17% at $10.80 after hours as the U.S. Food and Drug Administration granted Breakthrough Therapy designation for a cancer drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.